- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- CC-122, CC-223, Rituximab, CC-292
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 8
- States / cities
- Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- CC-122, Ibrutinib, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 8
- States / cities
- La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- CC-122, Dexamethasone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Nashville, Tennessee • Madison, Wisconsin
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Interventions
- JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Renal Insufficiency
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Lakewood, Colorado • Minneapolis, Minnesota
- Conditions
- Diffuse B-Cell Lymphoma
- Interventions
- Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion, Vincristine, Prednisone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • St Louis, Missouri
- Conditions
- Healthy Volunteers
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- CC-122, Nivolumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • New York, New York + 1 more
- Conditions
- Clinical Pharmacology, Healthy Male Volunteer Study
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Melanoma
- Interventions
- CC-122, Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- CC-122, Sorafenib
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
- Conditions
- Healthy Volunteer
- Interventions
- CC-122, Itraconazole, Fluvoxamine, Rifampin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas